Musculoskeletal Diseases Market

Global Musculoskeletal Diseases Market Size

The size of the global musculoskeletal diseases market was worth USD 5.62 billion in 2025. The global market is anticipated to grow at a CAGR of 6.12% from 2026 to 2034 and be worth USD 9.59 billion by 2034 from USD 5.96 billion in 2026.

Musculoskeletal diseases are injuries and disorders that affect the musculoskeletal system of the human body. The injuries and disorders include muscles, ligaments, nerves, tendons, spinal discs, and cartilage. The most common musculoskeletal diseases are osteoarthritis, gout, back pain, osteoporosis, and rheumatoid arthritis. Muscle tissue gets damaged with the wear and tear of daily activities, which causes musculoskeletal pain. The drugs for musculoskeletal disease treatment are muscle relaxants, anti-inflammatory drugs, antipyretics, and corticosteroids, commonly used worldwide. Many players dominate the musculoskeletal diseases market because of the highly fragmented and competitive landscape. Therefore, the musculoskeletal diseases market has been examined to present an in-depth market assessment based on past and present performance status.

MARKET DRIVERS

YOY rise in the incidence of musculoskeletal diseases is primarily propelling the musculoskeletal diseases market worldwide.

Musculoskeletal diseases cause increased workplace pressure, low fitness and health habits, and improper postures. Across the world, the number of people suffering from musculoskeletal conditions is growing significantly. As per the reports published by WHO, across the world, a total of 1.71 billion people are suffering from musculoskeletal conditions. According to recent reports, ligaments, tendons, cartilage, and spinal discs are musculoskeletal injuries and disorders rapidly increasing globally, expected to drive the market growth.

Increasing awareness among the people about musculoskeletal diseases, developing efficient and advanced technologies in developed countries, and commercialization of pipeline drugs are other primary factors driving the market growth.

Moreover, encouraging global government initiatives, increasing healthcare expenditure, and adopting musculoskeletal disease drugs are expected to favor market growth. Besides, the significant presence of unmet medical needs in developing countries is more likely to support market growth. Therefore, adopting musculoskeletal disease drugs provides lucrative opportunities for market players in emerging countries to propel the musculoskeletal diseases market. Technological advancements in the field of treatment help market growth.

The market is growing due to the continuous development of technologies used to diagnose and treat musculoskeletal diseases. Diagnosis instruments for musculoskeletal problems are now more flexible and have more feasibility. The latest techniques, like biologics, small molecules, stem cell research, and others, help improve the accuracy of treatment procedures and drugs. Procedures such as organ-on-a-chip, lab-on-a-chip, orthobiologics, gene therapy, etc., help improve treatment options for musculoskeletal disorders. Additionally, techniques like bone grafting help fix fractured bones. Therefore, better care services and intensive research and development are expected to support market expansion. 

MARKET RESTRAINTS

High costs associated with the R&D, stringent government rules, and a complex government approval process is expected to impede the musculoskeletal diseases market growth. In addition, the primary concern for the hospitals is that the risk of side effects of musculoskeletal disease treatment hinders market growth.

MARKET OPPORTUNITIES

Emerging therapies present potential growth prospects for the forecast period for the expansion of the musculoskeletal diseases market.

The landscape of treatments for orthopaedic conditions is gradually developing with the help of break-throughs in regenerative medicines, targeted drug delivery systems, biologics, and individualised medication approaches. The budding therapies possess the ability to considerably enhance results of patients battling from various musculoskeletal disorders by addressing basic causes. Under regenerative medicines both gene therapy and stem cell therapy are being explored.

Mesenchymal stem cells (MSCs) are currently investigated for their capability to repair and regenerate damaged tissues, including muscle, cartilage, and bone. It exhibited promising outcomes in treating conditions like osteoarthritis, degenerative disc disease, and tendon injuries. This is because of their anti-inflammatory and immune and-modulatory properties.

Technological advancements in another factor providing opportunities for market expansion.

• For instance, according to a study by NIHR Innovation Observatory on July 2024, total 109 unique technologies (including digital intervention and regulated medical devices) were found in specialised biomedical literature, health records, and clinical trial databases, along with publicly available information from companies trying to enter into the United Kingdom market.

The biggest share of innovative technologies came to light were being developing in the United States of America, and followed by the UK. Also, some technologies were being created in the European Union. Single and multiple MSK conditions were the two evenly split and identified technologies. Around 50 per cent of the novel ones were digital (like applications for mobile devices), devices were one-third (e.g., an innovative brace to help in mobility), and the remaining were devices with virtual elements (such as a digital pain-reduction kit). However, a large part of these break-through technologies did not integrate the application of artificial intelligence.

MARKET CHALLENGES

Inconsistent information from AI Chatbots has recently come to light. It is expected to become one of the major challenges obstructing the expansion of the musculoskeletal diseases market. Nowadays, these chatbots or conversational AI is rapidly gaining popularity among consumers as well as companies due to busy lifestyles, volatile economics, and work pressures. So, delivery of misleading or inaccurate can be detrimental to the human health and to the market growth. Likewise, with the surging acceptance of chatbots or virtual agents based on large language model (LLM), a kind of AI utilised by BingAI, Google Bard, and ChatGPT, it is essential to outline the precision of information of musculoskeletal diseases provided by them.

• According to a review published in the first quarter of 2024, when orthopaedic questions were asked to Google Bard, BingAI, and OpenAI’s ChatGPT, it provided right answers that resolved the important salient points in 33 per cent, 16.7 per cent, and 76.7 per cent of the inquiries, respectively.

At the 2024 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS), 3 new studies examined the dependability of information given by chatbots to people concerning specific orthopaedic procedures, evaluating the accuracy with which these virtual assistants convey research developments and medical decision-making processes. Even though the studies discovered that specific conversation bots give brief highlights over a broad range of orthopaedic conditions, everyone illustrated restricted correctness depending on the class.

Another research released in January 2024 on Open Exploration Journal cautioned professionals, experts and common people about the unreliability of output presented by chatbots.

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Type Insights

Based on type, rheumatoid arthritis has a high prevalence and therefore had the largest share of the market in 2025. The increasing geriatric population and rising chronic inflammatory disorders propel market growth. In addition, the uptake of new products in IL-6 and JAH inhibitors and the approval and launch of pipeline therapies are expected to increase the segment's growth.

However, the osteoarthritis segment is also expected to help the market grow. It is a prevalent condition due to the cartilage wearing off on bones, especially in the hips, knees, and hands. Around 32.5 million U.S. adults are affected by osteoarthritis, according to CDC. Therefore, the condition's prevalence is expected to support its dominance in the market. 

Additionally, ankylosing spondylitis segment is also expected to grow during the forecast period due to the rising cases of spondylitis worldwide. 

By Type of Molecules Insights

Based on the type of molecules, the biologics segment is expected to have the largest market share. Biologics have a complex structure that does not allow easy identification or characterization, which drives this segment. However, the biologics drugs are robust and work very well for patients with Rheumatoid arthritis, psoriatic, and other inflammatory arthritis. In addition, the products of biologics are heavily used in biopharmaceuticals for the creation of drugs and experimentation, further promoting the segment's growth.

However, the small molecules segment is also expected to grow during the forecast period due to the application of small molecules in drug discovery and finding information about gene expression. Small molecules are organic compounds with low molecular weight and can efficiently penetrate and react within intracellular levels like the cytoplasm. This tremendous advantage of the segment promises it a bright revenue in the future. 

By Treatment Insights

Based on the treatment, the corticosteroids segment held the largest market share in 2025. The segment's growth is expected to be driven by the growth factors such as increasing disposable income, advanced corticosteroids, and riding investments by the government to develop hospital infrastructure to ensure better treatments.

However, the synthetic bone graft and biologics market segments are expected to grow significantly during the forecast period. These two segments are relatively new and emerging, with research and development of many technologies to apply the treatment process supporting their growth. Furthermore, bone grafting is a beneficial process in case of bone fractures, and biologics help fix musculoskeletal issues. Therefore, the rising cases of accidents leading to fractures are supporting the growth of the segments. 

REGIONAL ANALYSIS

North America Musculoskeletal Diseases Market Analysis

Geographically, the North American musculoskeletal diseases market had the largest share of the world market in 2025, owing to the increased use of biological drugs for treating various musculoskeletal diseases, increased access to medical and healthcare facilities, and the introduction of novel biologics. The rising uptake of existing biologics drugs for various musculoskeletal disease treatments, increasing need for drug development, and novel biologics are expected to drive market growth in this region. In addition, access to this region's medical and healthcare facilities and increasing healthcare spending propel the musculoskeletal disease market.

Europe Musculoskeletal Diseases Market Analysis

The European musculoskeletal diseases market was the second-largest regional market and is anticipated to grow at a robust CAGR during the forecast period. An increase in pressure in workplaces leads to various musculoskeletal diseases. In addition, low fitness, health habits, and improper postures create the demand for musculoskeletal disease treatments, leading to market growth.

Asia Pacific Musculoskeletal Diseases Market Analysis

The Asia Pacific musculoskeletal diseases market is considered the fastest-growing regional market globally and is predicted to register the highest CAGR during the forecast period. Emerging countries, such as India and China, are experiencing muscular disorders due to increased work pressure. These countries witness significant market growth due to the rapid adoption of advanced treatments for musculoskeletal diseases. However, the market is projected to record better growth over the forecast period.

KEY MARKET PLAYERS

Some of the notable companies dominating the global musculoskeletal diseases market profiled in this report are

• AbGenomics International
• AB Sciences
• Ablynx
• Akron Molecules
• Johnson & Johnson
• F. Hoffmann-La Roche
• Pfizer
• Eli Lilly
• Adheron
• Alder BioPharmaceuticals
• Bioiberica
• Bone Therapeutics
• Edding Pharm
• Boehringer Ingelheim
• Can-Fite BioPharma
• Celltrion
• Celgene Corp.
• Cellular Biomedicine
• ChemoCentryx
• Cerapedics
• Eupraxia Pharmaceuticals
• GlaxoSmithKline

GLOBAL MUSCULOSKELETAL DISEASES MARKET NEWS

• In December 2024, the Department for Work and Pension (DWP) of the United Kingdom reported a new initiated intended to expedite treatment for people with musculoskeletal (MSK) conditions like muscle, joint, and back problems in regions with the prolonged waiting lists. This step is part of the ‘Get Britain Working’ white paper of the UK Government.
• In August 2024, Hoan My Medical Group announced the inauguration of an Orthopaedic and spine facility in the city of Ho Chi Minh in Vietnam for the treatment of musculoskeletal disorders. Moreover, as per the groups, the recently opened facility accepted the MRI 3.0 Tesla SISNA Hero system and artificial intelligence to focus on earlier diagnosing and damage identification. In addition, the center provides treatment and screening, like minimally invasive spinal procedures, meniscus repair, ligament reconstruction, artificial hip and knee replacement, and orthdopaedic trauma.
• In July 2023, the U.S. Food and Drug Administration permitted Elevidys, which is the foremost genetic therapy for curing the pediatric patients 4 through 5 years of age suffering from Duchenne muscular dystrophy (DMD) with affirmed mutation in the gene of DMD who do not have previous medical reason stopping remedy with this treatment.

MARKET SEGMENTATION

This research report on the global musculoskeletal diseases market is segmented and sub-segmented into the following categories.

By Type

• Rheumatoid Arthritis
• Osteoarthritis
• Osteoporosis
• Psoriatic Arthritis
• Ankylosing Spondylitis
• Fibromyalgia
• Others

By Type of Molecules

• Biologics
• Small Molecules

By Treatment

• Biologics
• Corticosteroids
• Parathyroid Hormone
• Protein Therapy
• Selective Estrogen Receptor Modulators
• Synthetic Bone Graft
• Composite Grafts
• Demineralized Bone Matrix
• BMPS

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa